Login to Your Account

VVUS Tumbles 55%

Vivus' Qnexa Likely to Face Delay, Handicapping Orexigen, Arena

By Trista Morrison

Monday, July 19, 2010
While many in the biotech industry were surprised when the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 10-to-6 against approval of Vivus Inc.'s obesity drug Qnexa (phentermine/topiramate) on Thursday, the aftermath was somewhat more predictable. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription